Webinars
September 25, 2025 | 1:00 – 2:00 PM ET
As U.S. leaders promote a drug pricing vision based on Most-Favored Nation (MFN) principles, ensuring that U.S. consumers have access to the best available prices among advanced nations, pharmaceutical companies are facing increased uncertainty and are evaluating strategic options.
This session will bring together Trinity experts to discuss how this initiative could realistically lead to changes in the market, including voluntary industry action, agency rulemaking, new legislation, and how these decisions may affect both U.S. and international markets. We will…
Sign Up Now
Blog
Published August 26, 2025
President Trump signed the “One Big Beautiful Bill Act” (OBBBA) into law on July 4, 2025. The OBBBA is projected to reduce federal health spending by an estimated $900 billion[1] over the next decade.
Central to the legislation is the estimated loss of insurance coverage for 16 million people[2], fundamentally reshaping access to care for millions and redefining the role of federal programs like Medicaid and the Affordable Care Act (ACA) Marketplaces. The biopharma industry will face a new set…
Read Now
Webinars
September 18, 2025 | 1:00 - 1:45 PM ET
Additional sessions will be offered on:September 22 – 12:00 (UTC +8:00) – AsiaSeptember 22 – 12:00 CET – Europe/Berlin
Medical Affairs teams are under growing pressure to deliver faster insights, smarter engagement, and measurable value—yet many are limited by manual processes, fragmented data, and time-intensive workflows.
Join us for the next webinar in our “AI Innovations in Life Sciences” series, where Trinity experts will show how it is possible with AI to unlock deeper, novel insights, power efficient workflows, and…
Sign Up Now
Blog
Published August 12, 2025
In today’s fast-evolving digital landscape, life sciences companies face a critical challenge: reach the right healthcare professionals (HCPs) with the right message, through the right channels, at the right time. At Trinity Life Sciences, we’re proud to help our clients meet that challenge head-on with the launch of Trinity Digital Affinity, powered by DeepIntent.
This breakthrough data offering unlocks new levels of visibility into the digital behavior of 3.5 million+ HCPs, enabling our clients not just to strategize—but to translate…
Read Now
Analyst Reports
Trinity Life Sciences is a Leader in Everest Group’s 2025 Life Sciences AI and Analytics Services for Commercial PEAK Matrix® Assessment—with its distinction rooted in exceptional, tangible outcomes delivered for clients across the life sciences sector.
More about the report
Everest Group’s PEAK Matrix® is a framework to assess the overall vision, capability and market impact of platform providers.
The assessment is based on Everest Group’s PEAK Matrix® Request For Information process for the calendar year 2024, interactions with leading life sciences…
Read Now
Briefs
Through the 2020s, life sciences leaders have dealt with one challenge after another. The shock of the COVID-19 pandemic. Sticky inflation. Return-to-office mandates. The intense pressure to perform in the face of disruptive challenges has proven constant.
For commercial learning and development, also known as commercial L&D, this has presented new roadblocks and innovations alike, making data more important than ever to navigate a rapidly changing industry. That’s why TGaS Advisors, a Division of Trinity Life Sciences, in partnership with…
Read Now
Briefs
How are Commercial, Medical and Market Access organizations evolving to develop capabilities and accelerate innovation in 2025 and beyond?
Executive leaders are focused on making informed organizational decisions to propel the evolution of capabilities in this rapidly changing global economy. As you strategize to optimize structure, talent and capabilities to excel in the future, this Advisory Brief brings you critical insights gleaned from the recent TGaS Advisors’ 2025 Spring Summit.
Complete the form below to access the advisory brief.
By submitting this form,…
Read Now
Webinars
Available On Demand
Medicare Part D is undergoing its most significant transformation in decades largely driven by the Inflation Reduction Act (IRA). What does this mean for pharmaceutical manufacturers?
Join us for an engaging discussion with Max Hunt, Partner at Trinity Life Sciences, and special guest Dan Simenc, clinical and actuarial expert at Milliman, as they provide perspectives on recent developments and future expectations for Medicare Part D and Medicare Advantage. The webinar will explore trends in drug spending, the impact of the…
Watch Now
Blog
Published July 1, 2025
China’s pharmaceutical landscape is not only vast in scale but also rapidly evolving with an emphasis on balancing access with affordability. This year’s NRDL update stands out. The introduction of the value rating system continues to raise the bar for clinical innovation, rewarding innovation that truly addresses unmet needs and demonstrates clear differentiation.
The National Reimbursement Drug List (NRDL) in China is a government-approved roster of medications that are covered by the national health insurance system. Inclusion on this list…
Read Now
Blog
Published June 25, 2025
Field sales serve as the primary bridge between companies and healthcare professionals to build trust, provide valuable information and drive product adoption. Effective call planning is essential, as it allows reps to prioritize their engagements, tailor messaging and maximize their impact.
The introduction of new technologies to streamline or enhance field operations comes with inherent challenges, such as resistance to change, training needs and aligning new systems with existing workflows. Quite simply, the field can become overwhelmed.
To overcome these…
Read Now
